BioTech
Workforce, capacity constraints slow ramp-up of new Alzheimer’s drug Leqembi
The first Alzheimer’s therapy to clearly slow cognitive decline, approved in the United States last month, lifted the hope of patients and their families. But
Robert Weisman — Boston Globe
August 30, 2023
